|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These preclinical data suggest that ex vivo-exPBNK modified with anti-CD20 CAR may have therapeutic potential for treating patients with poor-risk CD20(+) hematologic malignancies.
|
25492700 |
2015 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR T cells have shown dramatic effects against blood cancers, but they have had little impact on solid tumors.
|
25583818 |
2015 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the biosynthetic chimeric antigen receptor engineered T cell (CAR-T) strategy was developed and exhibited encouraging clinical efficacy, especially in hematological malignancies.
|
27009301 |
2016 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have demonstrated promising results against hematological malignancies, but have encountered significant challenges in translation to solid tumors.
|
27145250 |
2016 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review reports the history of adoptive immunotherapy using CAR-Ts, the CAR-T manufacturing process, and T cell therapies in development for hematological malignancies.
|
27865176 |
2016 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas much of the early success with CAR-T cells has been demonstrated with hematological malignancies, important barriers remain for the application of CAR-T cell therapies for the management of metastatic solid tumors.
|
27910858 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD19, CD20 chimeric antigen receptor T (CAR T) cell therapy has shown promising results for the treatment of relapsed or refractory hematological malignancies.
|
28128714 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This review summarizes difference of CAR T applications in solid and blood cancers.
|
28272967 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Initial data on donor-derived CAR T cells has shown this modality to be safe and highly effective in various hematological malignancies.
|
29032736 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Innovative approaches such as haploidentical stem cell transplantation, new monoclonal antibodies and immunotherapies as well as Chimeric Antigen Receptor T-cell (CAR-T cell) therapies are on the way as promising treatment options especially for patients with refractory hematologic malignancies and even in solid tumors.
|
29556955 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies.
|
29769134 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric antigen receptor-modified (CAR-modified) T cells have shown promising therapeutic effects for hematological malignancies, yet limited and inconsistent efficacy against solid tumors.
|
29769444 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because CAR-T therapy has shown great success in treating CD19-positive hematological malignancies, its application has been explored in the treatment of solid tumors, such as liver cancer.
|
29861325 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Adoptive transfer of autologous CAR-T cells can induce durable remissions in patients with relapsed/refractory hematologic malignancies.
|
29909917 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
T cell senescence and CAR-T cell exhaustion in hematological malignancies.
|
29973238 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome.
|
30075127 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we discuss the structure of the CAR, current clinical advantages from finished and ongoing trials, adverse effects, challenges and controversies, new engineering methods of CAR, and clinical considerations that are associated with CAR T cell therapy both in hematological malignancies and solid tumors.
|
30108584 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies.
|
30410941 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study offers a reference for future research regarding the application in solid and hematologic malignancies, side effects and relapse, and even the production processes of CAR T cells.
|
30621018 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review focuses on application of CAR-T cells in hematologic malignancies beyond targeting CD19, with specific attention to Hodgkin's lymphoma and acute myeloid leukemia.
|
30632631 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma.
|
30659408 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CAR-T has shown promise in a number of other hematologic malignancies, and toxicities have become more manageable as its use is becoming more widespread.
|
30715612 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite its revolutionary success in hematological malignancies, chimeric antigen receptor T (CAR-T) cell therapy faces disappointing clinical results in solid tumors.
|
30734529 |
2019 |